Antipsychotic Drugs Market Trends

  • Report ID: 6384
  • Published Date: Sep 04, 2024
  • Report Format: PDF, PPT

Antipsychotic Drugs Market Trends

Growth Drivers:

  • New developments in medication: With continuous research and development, second and third-generation antipsychotics are discovered with enhanced efficacy in reducing the side effects produced. For example, in January 2023, Luye Pharma Group was granted FDA approval to produce an extended-release injectable drug, Rykindo. This can be used in treating both schizophrenia and bipolar disorder. These act as growth drivers for the market, promising better outcomes from the treatment.
  • Integration with digital health technologies: The integration of digital health platforms will include telemedicine and wearable devices to monitor patients and enhance adherence to treatment with antipsychotic drugs. As per (National Institutes Studies (NIH) studies published in August 2023, the progressive role of telemedicine in bridging location-wise physical barriers to traditional healthcare with offline modes leads to possibly irreversible treatment advances in managing psychiatric conditions through remote care. This is expected to contribute to the further expansion of the market.

Challenges:

  • Regulatory challenges: A key challenge in the antipsychotic drugs market is the tough regulatory environment. The long period for the approval of new drugs shows that the regulatory norms are strict. In February 2023, a report from EMA detailed how stringent testing and approval processes could make it tough for manufacturers.
  • Side effects and patient compliance: Despite modern research and the development of drugs, antipsychotic agents are not without side effects. Weight gain, metabolic alterations, and sedation are some of the poor compliances reported in patients. (National Center for Biotechnology Information) NCBI published a study in March 2023 pinpointing the challenges surrounding antipsychotic drug manufacture and the need for better outcomes in treatment.

Antipsychotic Drugs Market: Key Insights:

Base Year

2023

Forecast Year

2024-2036

CAGR

5.8%

Base Year Market Size (2023)

USD 16.5 billion

Forecast Year Market Size (2036)

USD 34.3 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6384
  • Published Date: Sep 04, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The antipsychotic drugs market size was USD 16.5 billion in 2023.

The global antipsychotic drugs market size was US 16.5 billion in 2023 and is likely to reach USD 34.3 billion by the end of 2036, expanding at a CAGR of 5.8% over the forecast period, i.e., 2024-2036.

Eli Lilly and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, and Dr. Reddy's Laboratories, are some key players in the market.

The second-generation segment is expected to hold a leading share during the forecast period.

North America is projected to offer lucrative prospects with a share of 55.0% in 2024.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample